Spinal cord stimulation (SCS) is a key driver of the neuromodulation devices market, offering an effective alternative to opioids for chronic pain management. According to the Neuromodulation Devices Market report, SCS is the largest application segment, driven by the opioid crisis and favorable reimbursement policies.
What Is Spinal Cord Stimulation?
SCS involves implanting a device that delivers electrical impulses to the spinal cord, blocking pain signals from reaching the brain. It is used to treat chronic back pain, complex regional pain syndrome, and failed back surgery syndrome. Modern SCS systems offer high-frequency and burst stimulation modalities, improving efficacy.
Why Is SCS Growing?
Several factors drive this growth. First, the opioid crisis has accelerated demand for non-pharmacological pain management solutions. Second, favorable reimbursement policies — including CMS expansion of coverage for SCS trials — have increased patient access. Third, technological advancements, including closed-loop SCS, have improved outcomes.
Challenges and Opportunities
Despite its benefits, SCS is associated with high costs and surgical risks. However, opportunities in non-invasive SCS and AI-powered programming present significant growth potential. As technology advances, SCS is expected to become more accessible and effective.
People Also Ask
What is spinal cord stimulation?
Spinal cord stimulation involves implanting a device that delivers electrical impulses to the spinal cord to block pain signals.
What conditions are treated with SCS?
SCS is used to treat chronic back pain, complex regional pain syndrome, and failed back surgery syndrome.
The Road Ahead
As the opioid crisis continues and technology advances, SCS will remain a key driver of the neuromodulation devices market. Its growth reflects a broader trend toward non-pharmacological pain management.
Tags: #SpinalCordStimulation #ChronicPain #NeuromodulationDevices #OpioidCrisis #PainManagement
